Phase 3 Primary Central Nervous System Lymphoma Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled8 locationsNCT07104032
Recruiting
Phase 3
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Primary Central Nervous System Lymphoma
University Hospital Freiburg340 enrolled35 locationsNCT06830421
Recruiting
Phase 2Phase 3
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Primary Central Nervous System Lymphoma
Navy General Hospital, Beijing100 enrolled1 locationNCT02836158
Recruiting
Phase 2Phase 3
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Primary Central Nervous System Lymphoma
Navy General Hospital, Beijing100 enrolled1 locationNCT02657785